---
title: "Amgen Inc. Stock Underperforms Friday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302925153.md"
description: "Amgen Inc. (AMGN) shares fell 1.79% to $439.26 on Friday, underperforming compared to competitors like Johnson & Johnson and Pfizer during a broader market decline. The stock closed 2.60% below its 52-week high of $450.98. Trading volume was notably lower than the 50-day average."
datetime: "2026-10-23T20:34:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302925153.md)
  - [en](https://longbridge.com/en/news/302925153.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302925153.md)
generator: "portal-rs"
---

# Amgen Inc. Stock Underperforms Friday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Amgen Inc. (AMGN) slipped 1.79% to $439.26 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.52% to 7,623.68 and Dow Jones Industrial Average falling 1.23% to 52,215.16.

Amgen Inc. closed 2.60% short of its 52-week high of $450.98, which the company reached on October 22nd.

The stock underperformed when compared to some of its competitors Friday, as Johnson & Johnson (JNJ) fell 1.42% to $263.81, Pfizer Inc. (PFE) fell 1.28% to $30.03, and AbbVie Inc. (ABBV) rose 0.16% to $285.64.

Trading volume (1.7 M) remained 1.1 million below its 50-day average volume of 2.8 M.

Data source: Dow Jones Market Data, FactSet. Data compiled October 23, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

10-23-26 1634ET

### Related Stocks

- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)

## Related News & Research

- [Amgen Inc. $AMGN Shares Acquired by VestGen Advisors LLC](https://longbridge.com/en/news/303720186.md)
- [Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer](https://longbridge.com/en/news/302966836.md)
- [FDA warns Amgen over cancer drug promotional video](https://longbridge.com/en/news/303273297.md)
- [AMGN: DeLLphi-305 showed a significant survival benefit for first-line maintenance IMDELLTRA plus IMFINZI](https://longbridge.com/en/news/302970188.md)
- [Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer](https://longbridge.com/en/news/303091953.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**